SOLICITATION NOTICE
B -- BRCA1/2 mutation testing
- Notice Date
- 1/6/2004
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-40026-NG
- Response Due
- 1/22/2004
- Archive Date
- 2/6/2004
- Point of Contact
- Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
- E-Mail Address
-
holdcram@exchange.nih.gov, rs442i@nih.gov
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Clinical Genetics Branch (CGB), plans to procure BRCA1/BRCA2 mutation testing with Myriad Genetic Laboratories, Inc., 320 Wakara Way, Salt Lake City, Utah 84108. The supplies and services herein are commercial as defined in FAR Part 12, and this acquisition is being made in accordance with the test program for using simplified procedures for certain commercial items as authorized in FAR Part 13. The North American Industry Classification System code is 541710 and the business size standard is 500 employees. The Clinical Genetics Branch (CGB) is engaged in ongoing clinical genetics study of hereditary breast/ovarian cancer. CGB has a need to obtain complete sequencing of the two-breast/ovarian cancer susceptibility genes known as BRCA1 and BRCA2 as part of these research projects. In addition, the CGB has a need for mutation testing, which targets the three Ashkenazi founder BRCA mutations, and for single mutation testing in either BRCA1 or BRCA2 in selected individuals. Finally, CGB has a need for molecular testing for the presence of large deletions in the BRCA genes, which have been recently recognized as important contributors to hereditary breast/ovarian cancer susceptibility. The samples were derived from individuals who are members of families in which these two cancers have occurred with unusual frequency. These studies are part of a comprehensive, multidisciplinary, intramural research program within DCEG=s Human Genetics Program, which is focused upon elucidation of the entire spectrum of scientific and clinical issues related to familial and hereditary forms of cancer. The current acquisition represents an extension of prior work done for the Government by Myriad Genetics, under a Memorandum of Understanding executed between the provider and the National Cancer Institute in November 1999. The purpose of the MOU is to facilitate performance of these complex assays in support on NCI-sponsored clinical cancer genetics research. Under a previous purchase order number, NCI CGB submitted 80 DNA samples to Myraid Genetics for germline BRCA1/2 mutation testing. In addition, the CGB has the potential for requiring BRCA1/2 sequencing of a relatively large number of samples, project designated GOG -0199 (NCI-02-C-0268), which is a national cohort study of women at increased genetic risk of ovarian cancer. Many of these subjects will have at this time, through out the contract, undergone clinical BRCA1/2 mutation testing. In these subjects, the decision may be made to submit their DNA to Myriad as part of this current research protocol of hereditary breast/ovarian cancer. This information is vital to the research that is currently ongoing. Period of Performance: Base Year: upon award through twelve (12) months, with four (4), twelve (12) month option renewals if exercised; FAR Clause 52.217-8 Option to extend service (November 1999) and FAR Clause 52.217-9 Option to Extend the Term of the Contract (March 2000) apply. The requirement will be an indefinite delivery indefinite quantity (IDIQ) type order. Myriad Genetic Laboratories, Inc. is the only source known to the NCI that can provide the assay results for a large number of DNA samples derived from participants in ongoing clinical research studies. In order to insure comparability of subsequent assay results with those already performed, the current procurement is proposed as a sole source acquisition. Failure to do so could invalidate the cornerstone of these important research projects, i.e., the accurate, timely and reliable classification of study participants with regard to their BRCA1/2 germline mutation status. Myriad Genetics owns the patents on both the BRCA1 and the BRCA2 genes, and thus is the only commercial vendor available to perform the required work. This is not a request for competitive quotations. However, if any interested party believes it can provide the above supplies, it may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow NCI to determine if it can meet the above minimum specifications described herein. Capability statements must be received in the Contracting Office by 1:00 PM EST (local Washington D.C. time) on January 22, 2004. If you have questions, please contact Malinda Holdcraft, Purchasing Agent via electronic mail holdcram@excange.nih.gov or by fax at (301) 402-4513. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted.
- Place of Performance
- Address: NIH/NCI
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN00499037-W 20040108/040106211723 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |